23 citations
,
January 2016 in “Frontiers in immunology” This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.
June 2026 in “Drug Design Development and Therapy” This review critically examines recent progress in peptide-based treatments for pancreatic disorders, including tools and strategies for pancreatitis, diabetes, and pancreatic cancer, highlighting advancements in drug design and preclinical efficacy, while also detailing ongoing clinical trials and future directions in precision medicine.
54 citations
,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” This review discusses the potential of targeting glucocorticoid action as a treatment strategy for obesity and type-2 diabetes, highlighting promising animal study results but reports no new clinical findings.
May 2021 in “Letters in Applied NanoBioScience” This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.
2 citations
,
December 2010 in “Zhonghua neifenmi daixie zazhi” This study found that autologous nonmyeloablative hematopoietic stem cell transplantation may help some newly-onset type 1 diabetes patients become insulin-free, although gastrointestinal and other mild side effects were observed.